Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection

Vaccine

Volumn 31, Issue 32, 2013, Pages 3229-3235

  Garcia Angulo, Victor A ^a   Kalita, Anjana ^a   Torres, Alfredo G ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Bacterial ghost; Diarrhea; EHEC; Enterohemorrhagic E. coli; Murine model; Shiga toxin; Vaccine

Indexed keywords

BACTERIAL VACCINE; DNA; ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE; SHIGA TOXIN; SHIGA TOXIN 1B; SHIGA TOXIN 2B; SHIGA TOXIN A2; SHIGA TOXIN B1; UNCLASSIFIED DRUG;

BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIAL VIRULENCE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI INFECTION; FOOD CONTAMINATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BACTERIAL SECRETION SYSTEMS; CATTLE; DISEASE MODELS, ANIMAL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFLAMMATION; MICE; SHIGA TOXINS; VACCINES, DNA; VACCINES, SUBUNIT; VIRULENCE FACTORS;

EID: 84879463772     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.013     Document Type: Review

References (96)

1. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998, 11:142-201.
2. Farfan M.J., Torres A.G. Molecular mechanisms that mediate colonization of Shiga toxin-producing Escherichia coli strains. Infect Immun 2012, 80:903-913.
3. Blanco M., et al. Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from cattle in Spain and identification of a new intimin variant gene (eae-xi). J Clin Microbiol 2004, 42:645-651.
4. Karmali M.A., Gannon V., Sargeant J.M. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 2010, 140:360-370.
5. CDC, Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep, 2011;60:749-55.
6. Sheng H., et al. Role of Escherichia coli O157:H7 virulence factors in colonization at the bovine terminal rectal mucosa. Infect Immun 2006, 74:4685-4693.
7. Ferens W.A., Hovde C.J. Escherichia coli O157:H7: animal reservoir and sources of human infection. Foodborne Pathog Dis 2011, 8:465-487.
8. Schmidt M.A. LEEways: tales of EPEC, ATEC and EHEC. Cell Microbiol 2010, 12:1544-1552.
9. Yang J., et al. Virulence regulation in Citrobacter rodentium: the art of timing. Microb Biotechnol 2010, 3:259-268.
10. Tree J.J., et al. Controlling injection: regulation of type III secretion in enterohaemorrhagic Escherichia coli. Trends Microbiol 2009, 17:361-370.
11. Wong A.R., et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Mol Microbiol 2011, 80:1420-1438.
12. Tobe T., et al. An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci U S A 2006, 103:14941-14946.
13. Thomas N.A., et al. Hierarchical delivery of an essential host colonization factor in enteropathogenic Escherichia coli. J Biol Chem 2007, 282:29634-29645.
14. Kenny B., et al. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 1997, 91:511-520.
15. Campellone K.G. Cytoskeleton-modulating effectors of enteropathogenic and enterohaemorrhagic Escherichia coli: Tir, EspFU and actin pedestal assembly. FEBS J 2010, 277:2390-2402.
16. Misyurina O., et al. The role of Tir, EspA, and NleB in the colonization of cattle by Shiga toxin producing Escherichia coli O26:H11. Can J Microbiol 2010, 56:739-747.
17. Li Y., et al. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 2000, 68:5090-5095.
18. Jenkins C., et al. Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus. J Med Microbiol 2000, 49:97-101.
19. Stearns-Kurosawa D.J., et al. Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli. Infect Immun 2010, 78:2497-2504.
20. Mohawk K.L., O'Brien A.D. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J Biomed Biotechnol 2011, 2011:258185.
21. Caprioli A., et al. Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. J Infect Dis 1994, 169:208-211.
22. Takeda T., et al. Epidemiological study of hemolytic uremic syndrome associated with enterohemorrhagic Escherichia coli in Japan. Nihon Rinsho 1997, 55:693-699.
23. Zoja C., Buelli S., Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010, 25:2231-2240.
24. Marcato P., et al. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 2001, 183:435-443.
25. Torres A.G., Kaper J.B. Multiple elements controlling adherence of enterohemorrhagic Escherichia coli O157:H7 to HeLa cells. Infect Immun 2003, 71:4985-4995.
26. Tarr P.I., et al. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun 2000, 68:1400-1407.
27. Totsika M., et al. Molecular characterization of the EhaG and UpaG trimeric autotransporter proteins from pathogenic Escherichia coli. Appl Environ Microbiol 2012, 78:2179-2189.
28. Lloyd S.J., Ritchie J.M., Torres A.G. Fimbriation and curliation in Escherichia coli O157:H7: a paradigm of intestinal and environmental colonization. Gut Microbes 2012, 3:272-276.
29. Torres A.G., et al. Identification and characterization of lpfABCC'DE, a fimbrial operon of enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2002, 70:5416-5427.
30. Low A.S., et al. Cloning, expression, and characterization of fimbrial operon F9 from enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2006, 74:2233-2244.
31. Lim J.Y., Yoon J., Hovde C.J. A brief overview of Escherichia coli O157:H7 and its plasmid O157. J Microbiol Biotechnol 2010, 20:5-14.
32. Thorpe C.M., et al. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001, 69:6140-6147.
33. Miyamoto Y., et al. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell Microbiol 2006, 8:869-879.
34. Berin M.C., et al. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol 2002, 4:635-648.
35. Hauf N., Chakraborty T. Suppression of NF-kappa B activation and proinflammatory cytokine expression by Shiga toxin-producing Escherichia coli. J Immunol 2003, 170:2074-2082.
36. van Setten P.A., et al. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr Res 1998, 43:759-767.
37. Yen H., et al. NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog 2010, 6:e1001231.
38. Leyva-Illades D., et al. Regulation of cytokine and chemokine expression by the ribotoxic stress response elicited by Shiga toxin type 1 in human macrophage-like THP-1 cells. Infect Immun 2012, 80:2109-2120.
39. Proulx F., et al. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2002, 52:928-934.
40. Walle K.V., Vanrompay D., Cox E. Bovine innate and adaptive immune responses against Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants. Vet Immunol Immunopathol 2013, 152:109-120.
41. Mahajan A., et al. An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157:H7 with bovine intestinal epithelium. Cell Microbiol 2009, 11:121-137.
42. McNeilly T.N., et al. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine 2010, 28:1422-1428.
43. Hayashi F., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
44. Chitko-McKown C.G., et al. Gene expression profiling of bovine macrophages in response to Escherichia coli O157:H7 lipopolysaccharide. Dev Comp Immunol 2004, 28:635-645.
45. Stahl A.L., et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006, 108:167-176.
46. Taraktsoglou M., et al. Transcriptional profiling of immune genes in bovine monocyte-derived macrophages exposed to bacterial antigens. Vet Immunol Immunopathol 2011, 140:130-139.
47. Hoffman M.A., et al. Bovine immune response to shiga-toxigenic Escherichia coli O157:H7. Clin Vaccine Immunol 2006, 13:1322-1327.
48. Hurd H.S., Malladi S. An outcomes model to evaluate risks and benefits of Escherichia coli vaccination in beef cattle. Foodborne Pathog Dis 2012, 9:952-961.
49. Panda A., et al. Escherichia coli O157:H7 infection in Dutch belted and New Zealand white rabbits. Comp Med 2010, 60:31-37.
50. Mohawk K.L., et al. Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora. Microb Pathog 2010, 48:131-142.
51. Zotta E., et al. Development of an experimental hemolytic uremic syndrome in rats. Pediatr Nephrol 2008, 23:559-567.
52. García A., et al. Renal injury is a consistent finding in Dutch belted rabbits experimentally infected with enterohemorrhagic Escherichia coli. J Infect Dis 2006, 193:1125-1134.
53. Pacheco A.R., Sperandio V. Shiga toxin in enterohemorrhagic E. coli: regulation and novel anti-virulence strategies. Front Cell Infect Microbiol 2012, 2:81.
54. Calderon Toledo C., Arvidsson I., Karpman D. Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model. Infect Immun 2011, 79:2224-2233.
55. Mallick E.M., et al. A novel murine infection model for Shiga toxin-producing Escherichia coli. J Clin Invest 2012, 122:4012-4024.
56. Torres A.G. Intestinal pathogenic Escherichia coli. Vaccines for biodefense and emerging and neglected diseases 2009, Academic Press, Amsterdam. A.D.T. Barrett, L.R. Stanberry (Eds.).
57. Ishikawa S., et al. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immun 2003, 71:3235-3239.
58. Konadu E., et al. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect Immun 1999, 67:6191-6193.
59. Gordon V.M., et al. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect Immun 1992, 60:485-490.
60. Marcato P., et al. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun 2005, 73:6523-6529.
61. Akiyoshi D.E., et al. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect Immun 2005, 73:4054-4061.
62. Jeong K.I., et al. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunol 2010, 11:16.
63. Mohawk K.L., et al. Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 2010, 28:4777-4785.
64. Smith M.J., et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006, 24:4122-4129.
65. Tsuji T., et al. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 2008, 26:2092-2099.
66. Gao X., et al. Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2009, 27:2070-2076.
67. Oloomi M., Bouzari S., Ajdary S. Immune responses of mice immunized with active recombinant shiga toxin and its derivatives. Iran J Allergy Asthma Immunol 2008, 7:53-60.
68. Cai K., et al. Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2011, 29:946-952.
69. Bentancor L.V., et al. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol 2009, 16:712-718.
70. Rojas R.L., et al. Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 2010, 17:529-536.
71. Asper D.J., et al. Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol 2011, 18:1052-1057.
72. Potter A.A., et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004, 22:362-369.
73. Babiuk S., et al. Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice. Microb Pathog 2008, 45:7-11.
74. Fan H.Y., et al. Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Mol Biol Rep 2012, 39:989-997.
75. Wan C.S., et al. B-cell epitope KT-12 of enterohemorrhagic Escherichia coli O157:H7: a novel peptide vaccine candidate. Microbiol Immunol 2011, 55:247-253.
76. Cataldi A., et al. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008, 26:5662-5667.
77. Oliveira A.F., et al. Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. Microbiol Immunol 2012, 56:513-522.
78. Luan J., et al. Expression of EspA in Lactococcus lactis NZ9000 and the detection of its immune effect in vivo and vitro. Immunopharmacol Immunotoxicol 2010, 32:133-140.
79. Ahmed B., et al. Mucosal priming of the murine immune system against enterohemorrhagic Escherichia coli O157:H7 using Lactococcus lactis expressing the type III secretion system protein EspB. Vet Immunol Immunopathol 2013, 152:141-145.
80. Yu S., et al. Identification of a novel linear epitope on EspA from enterohemorrhagic E. coli using a neutralizing and protective monoclonal antibody. Clin Immunol 2011, 138:77-84.
81. Larzabal M., et al. Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorragic Escherichia coli O157:H7 and Citrobacter rodentium. Int J Med Microbiol 2013, 303:9-15.
82. Gu J., et al. Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009, 11:835-841.
83. Gu J., et al. Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice. Vaccine 2011, 29:7395-7403.
84. Fujii J., et al. Protection by a recombinant mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. Clin Vaccine Immunol 2012, 19(12):1932-1937.
85. Amani J., et al. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine 2010, 28:6923-6929.
86. Amani J., et al. Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci 2011, 180:620-627.
87. Shariati Mehr K., et al. A DNA vaccine against Escherichia coli O157:H7. Iran Biomed J 2012, 16:133-139.
88. Zhang X.H., et al. Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine 2011, 29:3923-3929.
89. Gao X., et al. Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice. Vaccine 2011, 29:6656-6663.
90. Cheng Y., et al. Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development. J Microbiol 2009, 47:498-505.
91. Liu J., et al. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Vaccine 2009, 27:5929-5935.
92. Lubitz P., Mayr U.B., Lubitz W. Applications of bacterial ghosts in biomedicine. Adv Exp Med Biol 2009, 655:159-170.
93. Cai K., et al. Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. Can J Microbiol 2010, 56:389-398.
94. Mayr U.B., et al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect Immun 2005, 73:4810-4817.
95. Mayr U.B., et al. Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb Biotechnol 2012, 5:283-294.
96. Vilte D.A., et al. A systemic vaccine based on Escherichia coli O157:H7 bacterial ghosts (BGs) reduces the excretion of E. coli O157:H7 in calves. Vet Immunol Immunopathol 2012, 146:169-176.